Palatin - חוב כולל להון PTN

The Palatin Technologies (PTN) price chart demonstrates a total debt-to-equity ratio of 0.03. Patent rights for peptide agents and strict FDA oversight serve as the business's defensive qualities. Palatin Technologies relies on the independent promotion of its primary drug while delegating sales in Europe and Asia to third-party partners. The development of treatments for inflammation and sexual dysfunction is conducted jointly with medical organizations.

The debt_total_eq_co ratio measures the proportion of borrowed funds within the financing structure, allowing investors to assess the balance between financial leverage and insolvency risk. Analyzing the debt-to-equity chart is critically important for Palatin Technologies (PTN), as a high reliance on external contractors (CRO/CMO) requires a sufficient equity cushion to cover operational risks.